

March 24, 2004

To Whom It May Concern

KYORIN Pharmaceutical Co., Ltd.
5, Kanda Surugadai 2-chome,
Chiyoda-ku, Tokyo
(Securities code: 4560; TSE 1st section)

Kyorin Announces the Filing of a Lawsuit
for Patent Infringement Against Teva in the United States.

KYORIN Pharmaceutical Co., Ltd. (Headquarters: Tokyo, President: Ikuo Ogihara) announces that on March 23, 2004 (U.S. time) it and Bristol-Myers Squibb Company filed a lawsuit against TEVA Pharmaceuticals USA, Inc. and TEVA Pharmaceutical Industries Ltd. in the United States District Court for the Southern District of New York alleging infringement of Kyorin's U.S. Patent 4,980,470 covering quinolone antibacterial compounds. The lawsuit was filed in response to TEVA's submission of an abbreviated new drug application (ANDA) to market a generic version of Tequin[®] (INN: gatifloxacin).